课题基金 / 基金详情

III: Small: Collaborative Research: Social Media Based Analysis of Adverse Drug Events: User Modeling, Signal Reliability, and Signal Validation

III: Small: Collaborative Research: Social Media Based Analysis of Adverse Drug Events: User Modeling, Signal Reliability, and Signal Validation
III:小:协作研究:基于社交媒体的药物不良事件分析:用户建模、信号可靠性和信号验证
批准号:
2039915
负责人:
Ahmed Abbasi
金额:
$15.61万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-25 至 2023-07-31

项目摘要

项目成果

Ahmed Abbasi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Adverse drug reactions (ADRs) have been associated with significant morbidity and mortality, and have been a significant cause of hospital admissions, accounting for as much as 5% of all admissions. About 2,000,000 serious ADRs are reported yearly in the US; 100,000 annual deaths are related to adverse drug events; serious ADRs rank 4th to 6th as causes of death. The problem stems from the fact that the ADR profile of a given drug is rarely complete at the time of official approval. The typically limited preapproval evaluation often results in the possibility that when the drug is finally approved for use in the general population (with significant diversity in race, gender, age, lifestyle), some previously unidentified ADRs are often observed. This problem is acute for psychotropic medications, given the fact that most people with psychiatric diseases tend to have other health issues, with the individual taking multiple drugs at the same time (both psychotropic and non-psychotropic), with often unknown interactions between them. Initial results have shown the promise of using social-media data for ADR signal detection. However, these methods are still faced with two critical challenges, namely, signal reliability and biological validation. Thus, this project proposes a detailed study on key determinants of signal reliability: credibility of social media sources, model of the users that generate source content, signal generation from such sources, and validation of the generated signals. This work will be relevant to government agencies charged with drug approval, drug monitoring, and disease monitoring, drug companies, hospitals, and the general public. The impact of the proposed work will go beyond drug surveillance, since the approaches proposed can be adapted for other healthcare problems, and for other scenarios, such as financial markets, and national security. Planned educational activities include outreach to high-school students, and involvement of undergraduate and graduate students. Research results will be disseminated via technical publications in professional journals and conference presentations. The project has three specific aims: (1) Enrich signal reliability in social media analysis of adverse drug events, using credibility analysis, user modeling and signal fusion via deep learning; (2) Signal validation via molecular level analysis; (3) Prototype development and evaluation. The ubiquity, veracity and diversity of data from various social media channels and other sources of user-generated content necessitate a serious consideration of their credibility, recency, uniqueness and salience. To enrich signal reliability, the team will propose novel methods for ADR signal detection using credibility analysis, and for user modeling and signal fusion based on deep leaning techniques. For signal validation, biological support for hypothesized ADRs, essentially connecting high-level observations from social media interactions to potential associations at molecular level networks and pathways, will be used. The results will change the current largely passive approach to post-marketing drug surveillance that relies heavily on voluntary reports, by ensuring reliability in social-media based approaches, thus making the public an integral part of a proactive drug surveillance system. The idea of signal fusion and deep learning for user modeling and signal generation can be extended for other uses beyond drug surveillance.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1145/3578931
发表时间: 2023-01
期刊: ACM Transactions on Information Systems
影响因子: 5.6
作者: [S. Somanchi;A. Abbasi;Ken Kelley;David G. Dobolyi;T. Yuan]
通讯作者: S. Somanchi;A. Abbasi;Ken Kelley;David G. Dobolyi;T. Yuan
DOI: 10.1287/isre.2022.1111
发表时间: 2022-03
期刊: Inf. Syst. Res.
影响因子: --
作者: [Kai Yang;Raymond Y. K. Lau;A. Abbasi]
通讯作者: Kai Yang;Raymond Y. K. Lau;A. Abbasi
Timely, Granular, and Actionable: Designing a Social Listening Platform for Public Health 3.0
及时、精细且可操作:为公共卫生 3.0 设计社交聆听平台
DOI: --
发表时间: 2024
期刊: Management information systems quarterly
影响因子: --
作者: [Kitchens, Brent, Claggett, Jennifer, Abbasi, Ahmed]
通讯作者: Abbasi, Ahmed
DOI: 10.18653/v1/2022.acl-long.72
发表时间: 2022
期刊:
影响因子: --
作者: [Yue Guo-;Yi Yang;A. Abbasi]
通讯作者: Yue Guo-;Yi Yang;A. Abbasi
10
    III: Small: Collaborative Research: Social Media Based Analysis of Adverse Drug Events: User Modeling, Signal Reliability, and Signal Validation
    • 批准号:
      1816504
    • 项目类别:
      Standard Grant
    • 资助金额:
      $23.0万
    • 财政年份:
      2018
    • 负责人:
      Ahmed Abbasi
    • 依托单位:
    EAGER: Collaborative Research: CRUFS: A Unified Framework for Social Media Analysis of Adverse Drug Events
    • 批准号:
      1553109
    • 项目类别:
      Standard Grant
    • 资助金额:
      $11.0万
    • 财政年份:
      2015
    • 负责人:
      Ahmed Abbasi
    • 依托单位:
    EAGER: Collaborative Research: Computational Public Drug Surveillance
    • 批准号:
      1236970
    • 项目类别:
      Standard Grant
    • 资助金额:
      $5.01万
    • 财政年份:
      2012
    • 负责人:
      Ahmed Abbasi
    • 依托单位:
    国内基金
    海外基金
    昼夜节律性small RNA在血斑形成时间推断中的法医学应用研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2024
    • 负责人:
    • 依托单位:
    tRNA-derived small RNA上调YBX1/CCL5通路参与硼替佐米诱导慢性疼痛的机制研究
    • 批准号:
    • 项目类别:
      省市级项目
    • 资助金额:
      10.0万元
    • 批准年份:
      2022
    • 负责人:
      张祥忠
    • 依托单位:
    Small RNA调控I-F型CRISPR-Cas适应性免疫性的应答及分子机制
    Small RNAs调控解淀粉芽胞杆菌FZB42生防功能的机制研究
    • 批准号:
      31972324
    • 项目类别:
      面上项目
    • 资助金额:
      58.0万元
    • 批准年份:
      2019
    • 负责人:
      高学文
    • 依托单位: